Girija Raman - 11.     Tharp, D.L., Wamhoff, B.R., Wulff, H., Raman, G., Cheong, A., Bowles, D.K. TRAM-34 prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis

Version 1

      Publication Details (including relevant citation   information): 11. Tharp, D.L., Wamhoff, B.R., Wulff, H.,   Raman, G., Cheong, A., Bowles, D.K. TRAM-34 prevents acute   angioplasty-induced coronary smooth muscle phenotypic modulation   and limits stenosis. 2008. Arterioscler. Thromb. Vasc. Biol. 28,   1084-1089. 12. Toyama, K., Wulff, H., Chandy, K.G., Azam,P.,   Raman, G., Saito,T., Fujiwara, Y., Gutterman, D.D., Mattson,   D.L., Das,S., Melvin, J.E., Pratt, P.F., Harder, D.H.., Miura, H.   Role of the Intermediate-conductance Calcium-activated Potassium   Channel, KCa3.1, in Cellular Activation and Atherogenesis. 2008.   J. Clin. Invest. 118(9), 3025-37. PMC2496961 13.   Sankaranarayanan, A., Raman, G., Zimin, P., Hoyer, J., Kohler,   R., Wulff, H. SKA-31, a New Activator of KCa2 and KCa3.1   Potassium Channels, Potentiates the EDHF Response and Lowers   Blood Pressure 2009, Molecular Pharmacology, 75, 289-295. 14.   Grgic, I., Kloss, M., Kiss, E., Sautter, J., Kaistha,   A.,Muller,A., Kaistha, B.P., Timphus, E.M.,Raman, G., Wulff, H.,   Struz, F., Grone,H.J., Kohler, R., Hoyer, J. 2009, PNAS, Renal   Fibrosis is attenuated by targeted disruption of KCa3.1 potassium   channels 2009, PNAS, 106(34),14518-23. 15. Al-Ghananeem AM,   Abbassi M, Shrestha S, Raman G, Wulff H, Pereira L, Ansari A.   Formulation-based approach to support early drug discovery and   development efforts: a case study with enteric microencapsulation   dosage form development for a triarylmethane derivative TRAM-34;   a novel potential immunosuppressant. Drug Dev Ind Pharm. 2009 Nov   24. [Epub ahead of print]

      Abstract: null

      Address (URL):